Purchase this article with an account.
Min Gyu Lee, Sang Jin Kim, Don-Il Ham, Se Woong Kang, Changwon Kee, Jaejoon Lee, Hoon-Suk Cha, Eun-Mi Koh; Macular Retinal Ganglion Cell–Inner Plexiform Layer Thickness in Patients on Hydroxychloroquine Therapy. Invest. Ophthalmol. Vis. Sci. 2015;56(1):396-402. doi: https://doi.org/10.1167/iovs.14-15138.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We evaluated macular ganglion cell-inner plexiform layer (GC-IPL) thickness using spectral-domain optical coherence tomography (SD-OCT) in patients with chronic exposure to hydroxychloroquine (HCQ).
This study included 130 subjects, who were divided into three groups: Group 1A, 55 patients with HCQ use ≥5 years; Group 1B, 46 patients with HCQ use <5 years; and Group 2, 29 normal controls. In all patients with exposure to HCQ, fundus examination, automated threshold perimetry, fundus autofluorescence photography, SD-OCT, and GC-IPL thickness measurement using the Cirrus HD-OCT ganglion cell analysis algorithm were performed. Average and minimum macular GC-IPL thickness were compared between subjects groups, and correlations between GC-IPL thickness and duration or total dose of HCQ use were analyzed.
Among the 101 patients of Group 1, six patients who showed clinically evident HCQ retinopathy also showed markedly thin macular GC-IPL. In addition, weak but significant negative correlations were observed between the average and minimum GC-IPL thickness of Group 1 patients and cumulative dose of HCQ, even when analyzing without the six patients with HCQ retinopathy. However, when analyzing after exclusion of patients with high cumulative doses (>1000 g), significant correlations were not observed.
This study revealed that macular GC-IPL thickness did not show definite correlations with HCQ use. However, some patients, especially with HCQ retinopathy or high cumulative doses, showed thin GC-IPL.
This PDF is available to Subscribers Only